Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00442520
Status:
COMPLETED
Last Update Posted:
2016-11-28
First Post:
2007-03-01
Brief Title:
Pharmacogenomic Study in Patients of Lung Colorectal and HeadNeck Cancers Receiving Chemotherapy
Sponsor:
University of Kansas Medical Center
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
Pharmacogenomic Study in Patients of Lung Colorectal and HeadNeck Cancers Receiving Chemotherapy
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to look at several genes that might determine how the body processes the drugs used to treat lung colorectal and head and neck cancers The goal of this examination is to help investigators determine the proper dosage to give future cancer patients or to better predict which future patients will respond to particular drug therapies
Detailed Description:
This study is to establish a pilot pharmacogenomic program in identifying genetic variation to predict the safety toxicity andor efficacy of drugs DNA will be extracted from patients peripheral blood to study SNPs in DPD TS MTHFR UGT1A1 CYP3A4 CYP3A5 GSTM1 GSTT1 GSTP1 HO-1 ERCC1 XPD XRCC1 and EGFR genes The results of genetic study will be compared to treatment efficacy and toxicity The ultimate goal is to use genotype profiles to provide individualized cancer treatment to improve outcome and decrease toxicity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None